Kidney Fibrosis Treatment Global Market Report 2026

Description

Kidney fibrosis treatment refers to therapeutic approaches aimed at slowing, stopping, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis involves the excessive buildup of extracellular matrix proteins, such as collagen, leading to scarring and impaired kidney function, and is commonly associated with chronic kidney disease (CKD).

The primary treatment types for kidney fibrosis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. ACE inhibitors help lower blood pressure and reduce strain on the heart by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis typically involves blood and urine tests, imaging scans, and kidney biopsies. These treatments are used for chronic kidney disease, kidney cancer, and other conditions, and are utilized by clinics, research centers, and hospitals.

Tariffs have affected the kidney fibrosis treatment market by increasing costs of imported active pharmaceutical ingredients, diagnostic equipment, and advanced therapeutic agents. These impacts are most significant in antifibrotic drugs and advanced diagnostic procedures, particularly across North America, Europe, and Asia-Pacific. Higher tariffs have contributed to increased treatment costs in hospitals and specialty clinics. On the positive side, tariffs have encouraged domestic pharmaceutical manufacturing and accelerated local development of kidney fibrosis therapies.

The kidney fibrosis treatment market research report is one of a series of new reports from The Business Research Company that provides kidney fibrosis treatment market statistics, including kidney fibrosis treatment industry global market size, regional shares, competitors with a kidney fibrosis treatment market share, detailed kidney fibrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment industry. This kidney fibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney fibrosis treatment market size has grown strongly in recent years. It will grow from $6.06 billion in 2025 to $6.54 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, limited effectiveness of conventional therapies, increased use of ace inhibitors and arbs, growing healthcare burden of renal failure, expansion of nephrology care services.

The kidney fibrosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in targeted antifibrotic agents, increasing aging population with ckd, growing adoption of precision medicine in nephrology, rising investment in renal research, improved early-stage kidney disease diagnosis. Major trends in the forecast period include increasing focus on antifibrotic drug development, growing use of combination therapies for ckd, rising research in stem cell and regenerative therapies, expansion of early diagnostic and monitoring tools, increasing clinical trials targeting renal fibrosis pathways.

The rising prevalence of chronic kidney diseases is expected to drive the growth of the kidney fibrosis treatment market in the coming years. Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function over time, often resulting from conditions such as diabetes or hypertension, which lead to the accumulation of waste products in the body. The growing prevalence of CKD is primarily driven by increasing rates of diabetes, which damage kidney blood vessels and impair their filtering capacity. Treatments for kidney fibrosis help CKD patients by targeting kidney tissue scarring, reducing inflammation, and slowing the progression of kidney damage, thereby preserving kidney function. For example, in July 2025, according to Hamadan University of Medical Sciences, an Iran-based institution, the global number of newly diagnosed chronic kidney disease cases is projected to reach 25.06 million by 2030. Consequently, the increasing prevalence of chronic kidney diseases is fueling the expansion of the kidney fibrosis treatment market.

Major companies in the kidney fibrosis treatment market are focusing on targeted ileal-release immunomodulatory therapies, such as NEFECON, an oral delayed-release budesonide capsule designed to deliver the drug specifically to the distal ileum. This approach modulates gut-associated B-cells and reduces pathogenic IgA production, slowing the progression of kidney fibrosis in patients with IgA nephropathy. For example, in June 2024, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON. The therapy utilizes an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the underlying cause of IgA nephropathy, and has demonstrated the ability to significantly slow the decline of kidney function.

In April 2025, Novartis, a Switzerland-based pharmaceutical company with a broad pipeline in renal and rare-disease therapies, acquired Regulus Therapeutics for an undisclosed amount. Through this acquisition, Novartis aimed to strengthen its kidney-disease franchise by obtaining Regulus's lead RNA-therapeutic candidate, farabursen, a microRNA-17 inhibitor for autosomal dominant polycystic kidney disease (ADPKD), enhancing its renal therapy pipeline. Regulus Therapeutics is a US-based (San Diego) biopharmaceutical company focused on developing first-in-class microRNA therapeutics, including farabursen for ADPKD.

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Fibrosis Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses kidney fibrosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney fibrosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kidney fibrosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors; Angiotensin Ii Receptor Blockers (Arbs); Pirfenidone; Renin Inhibitors; Vasopeptidase Inhibitors; Other Treatment Types
2) By Diagnosis: Blood Tests; Urine Tests; Imaging Tests
3) By Application: Chronic Kidney Diseases; Kidney Cancer Treatment; Other Applications
4) By End-User: Clinics; Research Center; Hospitals
Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril; Captopri; Lisinopril; Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan; Telmisartan; Valsartan; Irbesartan
3) By Pirfenidone: Branded Pirfenidone; Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren; Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat; Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents; Stem Cell Therapy; Antifibrotic Agents Under Clinical Trials; Gene Therapy
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; AstraZeneca PLC; Gilead Sciences Inc.; Novo Nordisk A/S; Boehringer Ingelheim International GmbH; Chinook Therapeutics Inc.; Akebia Therapeutics Inc.; Travere Therapeutics Inc.; Reata Pharmaceuticals Inc.; ProKidney LLC; Tvardi Therapeutics Inc.; Alentis Therapeutics AG; Galecto Biotech AB; Vertex Pharmaceuticals Incorporated; Insilico Medicine Inc.; Purespring Therapeutics Inc.; La Jolla Pharmaceutical Company; Cara Therapeutics Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MKFTI01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Kidney Fibrosis Treatment Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Kidney Fibrosis Treatment Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Kidney Fibrosis Treatment Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Kidney Fibrosis Treatment Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Increasing Focus On Antifibrotic Drug Development
- 4.2.2 Growing Use Of Combination Therapies For Ckd
- 4.2.3 Rising Research In Stem Cell And Regenerative Therapies
- 4.2.4 Expansion Of Early Diagnostic And Monitoring Tools
- 4.2.5 Increasing Clinical Trials Targeting Renal Fibrosis Pathways

5. Kidney Fibrosis Treatment Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Nephrology Clinics
5.3 Research Centers
5.4 Dialysis Centers
5.5 Specialty Renal Care Clinics

6. Kidney Fibrosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Kidney Fibrosis Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Kidney Fibrosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Kidney Fibrosis Treatment Market Size, Comparisons And Growth Rate Analysis
7.3. Global Kidney Fibrosis Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Kidney Fibrosis Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Kidney Fibrosis Treatment Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Kidney Fibrosis Treatment Market Segmentation

9.1. Global Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types
9.2. Global Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Blood Tests, Urine Tests, Imaging Tests
9.3. Global Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications
9.4. Global Kidney Fibrosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Clinics, Research Center, Hospitals
9.5. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (Ace) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Enalapril, Captopri, Lisinopril, Ramipril
9.6. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin Ii Receptor Blockers (Arbs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Losartan, Telmisartan, Valsartan, Irbesartan
9.7. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Branded Pirfenidone, Generic Pirfenidone
9.8. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Aliskiren, Experimental Renin Inhibitors
9.9. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Vasopeptidase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Omapatrilat, Sampatrilat
9.10. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

10. Kidney Fibrosis Treatment Market Regional And Country Analysis

10.1. Global Kidney Fibrosis Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Kidney Fibrosis Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Kidney Fibrosis Treatment Market

11.1. Asia-Pacific Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Kidney Fibrosis Treatment Market

12.1. China Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Kidney Fibrosis Treatment Market

13.1. India Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Kidney Fibrosis Treatment Market

14.1. Japan Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Kidney Fibrosis Treatment Market

15.1. Australia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Kidney Fibrosis Treatment Market

16.1. Indonesia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Kidney Fibrosis Treatment Market

17.1. South Korea Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Kidney Fibrosis Treatment Market

18.1. Taiwan Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Kidney Fibrosis Treatment Market

19.1. South East Asia Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Kidney Fibrosis Treatment Market

20.1. Western Europe Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Kidney Fibrosis Treatment Market

21.1. UK Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Kidney Fibrosis Treatment Market

22.1. Germany Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Kidney Fibrosis Treatment Market

23.1. France Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Kidney Fibrosis Treatment Market

24.1. Italy Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Kidney Fibrosis Treatment Market

25.1. Spain Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Kidney Fibrosis Treatment Market

26.1. Eastern Europe Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Kidney Fibrosis Treatment Market

27.1. Russia Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Kidney Fibrosis Treatment Market

28.1. North America Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Kidney Fibrosis Treatment Market

29.1. USA Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Kidney Fibrosis Treatment Market

30.1. Canada Kidney Fibrosis Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Kidney Fibrosis Treatment Market

31.1. South America Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Kidney Fibrosis Treatment Market

32.1. Brazil Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Kidney Fibrosis Treatment Market

33.1. Middle East Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Kidney Fibrosis Treatment Market

34.1. Africa Kidney Fibrosis Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Segmentation By Diagnosis, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Kidney Fibrosis Treatment Market Regulatory and Investment Landscape

36. Kidney Fibrosis Treatment Market Competitive Landscape And Company Profiles

36.1. Kidney Fibrosis Treatment Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Kidney Fibrosis Treatment Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Kidney Fibrosis Treatment Market Company Profiles
- 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Kidney Fibrosis Treatment Market Other Major And Innovative Companies

Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc.

38. Global Kidney Fibrosis Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Kidney Fibrosis Treatment Market

40. Kidney Fibrosis Treatment Market High Potential Countries, Segments and Strategies

40.1 Kidney Fibrosis Treatment Market In 2030 - Countries Offering Most New Opportunities
40.2 Kidney Fibrosis Treatment Market In 2030 - Segments Offering Most New Opportunities
40.3 Kidney Fibrosis Treatment Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer